Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Clinical research

Anti-inflammatory asthma drug could treat type 2 diabetes

Researchers have found that a repurposed anti-inflammatory and anti-allergic drug previously developed for asthma improved blood glucose control in people with type 2 diabetes and non-alcoholic fatty liver disease.

The study[1], published in Cell Metabolism, involved 42 obese patients with type 2 diabetes who were randomly assigned to receive amlexanox or placebo for 12 weeks.

Overall, patients who received the drug had a significantly greater reduction in haemoglobin A1c (HbA1c) levels than those who received placebo. Fructosamine levels, a marker of shorter term glucose control, were also significantly different between the two groups, as was fasting blood glucose.

However, further analysis showed a discrepancy in how patients responded to the drug, with only seven (around a third) of those who received it experiencing a clinically meaningful HbA1c reduction.

The researchers found that these “responders” had a much greater reduction in fructosamine than the overall cohort and also showed improvements in insulin sensitivity and liver fat loss.

By studying gene expression in subcutaneous fat samples, the researchers found that responders had a unique pattern of gene expression from non-responders that indicated a higher baseline level of inflammation.

Also, samples taken at the end of the study showed changes in gene expression that pointed towards increased fuel oxidisation and insulin sensitivity, which had previously also been observed in treated mice. 

Amlexanox was developed in Japan in the 1980s and has been studied for the treatment of asthma, allergic rhinitis and aphthous ulcers. The drug works by inhibiting two enzymes involved in inflammation that were found to be elevated in obese people.

The researchers say that it is still early days for its potential application in diabetes and much more research will be needed. They plan to explore whether responders can be selected at baseline and combining the drug with other diabetes or obesity therapies. 

“The most exciting part of this is that we have a new drug that has never been studied before,” said lead author Alan Saltiel from the University of California San Diego School of Medicine. “It’s a new mechanism for a diabetes and fatty liver drug. It’s promising, but there are a lot of questions that still need to be answered.”

Citation: The Pharmaceutical Journal URI: 20203132

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Back of obese woman

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.